To be notified of PMedIC updates: Request to be added to the mailing list.
Individual differences in genes and proteins can allow a disease to develop, grow, and spread in one person but not another, and also dictate how individuals respond to treatments. This insight has produced a new discipline—precision medicine—in which doctors integrate multiple measurements on each patient, including their genes, proteins and medical images, to help select prevention and treatment strategies that are tailored to each individual.
Oregon Health & Science University and the U.S. Department of Energy's Pacific Northwest National Laboratory launched the Precision Medicine Innovation Co-Laboratory (PMedIC) in February 2018. PMedIC aims to generate, interpret, and apply multidimensional patient data such as genetic, proteomic, and metabolic profiles, and integrate this information with imaging and clinical results, to transform precision medicine.
PMedIC has three integrated components: data science, imaging, and 'omics, as shown in the figure below. Each component has its own research partners, leadership, and projects, thus bringing to bear the best minds, capabilities, and instrumentation for each area.
PMedIC will also act as a clearinghouse for researchers, matching them to subject matter experts at both OHSU and PNNL. It will also assist in putting together teams for the development of joint proposals, help investigators identify sources of funding for pilot projects, and offer assistance with proposal management.
New insights from PMedIC's approach will inform clinical trials, leading to more customized treatments and better patient outcomes.
View the PMedIC flier.
Pacific NW Partnership for Data Intensive Biological Science
Proposed Northwest Center for CryoEM
PMedIC Co-Director Dr. Karin Rodland talks about the promise of precision medicine: "I dream of a day when no one has to die because of cancer."
Hear how OHSU's Knight Cancer Institute is personalizing medicine for its patients.
Dr. Karin Rodland talks about identifying the proteins in ovarian tumors—the first step to targeting drugs for specific individuals.
Meet the scientists of OHSU.